Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Thailand
/
Pharmaceuticals & Biotech
Create a narrative
Pharmaceuticals & Biotech Thai Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Pharmaceuticals & Biotech Thai Investing Ideas
All companies
Popular
Undervalued
Overvalued
Mega Lifesciences
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Key Takeaways Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth. Diversified product pipeline and focus on preventive healthcare align with rising demand, driving consistent earnings momentum and unlocking higher value per unit.
View narrative
฿32.57
FV
6.4% undervalued
intrinsic discount
0.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
6 days ago
author updated this narrative
Mega Lifesciences
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Myanmar Scrutiny And FX Risks Will Dampen Prospects With Upside
Key Takeaways Reliance on traditional products and lack of innovation risk shrinking market relevance and long-term growth opportunities amid evolving consumer preferences. Regulatory, geopolitical, and competitive pressures are likely to drive up costs, increase earnings volatility, and compress margins, challenging overall profitability.
View narrative
฿26.00
FV
17.3% overvalued
intrinsic discount
-0.74%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Mega Lifesciences
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Aging Populations And Emerging Markets Will Drive Wellness Demand
Key Takeaways Accelerated manufacturing expansion, robust product pipeline, and localization strategies position Mega Lifesciences for outperformance in topline growth and margin resilience. Early focus on prevention-oriented brands and proactive market adaptation may lead to dominant status and sustained earnings growth amid evolving health trends.
View narrative
฿39.00
FV
21.8% undervalued
intrinsic discount
5.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
14 days ago
author updated this narrative
Value any company in seconds
Popular companies